MRK

Merck & Co Inc

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 146.95 Healthcare - Drug Manufacturers - GeneralAWAIT ENTRY

ACTIONABLEMethodology gates passed

Position levels

Currenttoday

USD 146.95

Buy <=wait / entry

USD 120.00

Trim >=take some off

USD 150.00

Thesis breakA Complete Response Letter or extended FDA review on a major pipeline asset, or ...

Scenario-weighted conviction

	Probability	Score	Contribution
Bull case	19%	100 / 100	19.0
Base case	50%	62 / 100	31.0
Bear case	31%	10 / 100	3.1
Weighted conviction			53 / 100 - OPPORTUNISTIC BUY

Top risks

M&A activity including acquisitions of Terns Pharmaceuticals and Cidara Therapeutics
Strategic licensing deals including $2.13B KRAS G12D cancer drug and $510M Protillion Biosciences partnership
Moderna cancer vaccine partnership with promising Q3 2026 results driving 13.7% revenue rise

Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.